Rockwell Medical's Potential for Exponential Gains

Rockwell Medical (NASDAQ:RMTI) has the potential for significant stock price gains by 2012 based on the enhanced earnings power of at least $4/share at that time for its lead clinical compound Soluble Ferric Pyrophosphate [SFP] with just a 20% share of the estimated $600 million U.S. market for iron replacements in 2012. The stock appreciation potential for RMTI is similar to the exponential gains experienced by AMAG Pharma (NASDAQ:AMAG) from the earlier part of this decade, culminating in approval of its IV iron replacement drug Feraheme earlier this year.

However, Rockwell is unique because it is not merely a development-stage operation, as its core dialysate business already generates significant revenue exceeding $50 million, which also serves as a built-in distribution channel for a differentiated form (compared to existing IV iron therapies) of dialysate iron replacement, SFP, upon successful clinical development and FDA approval. In addition, there is a very low clinical risk for SFP based on its excellent safety record and well-established mode of action as an add-on to the Company’s core business as a dialysate iron replacement therapy that has the potential for additional applications and indications beyond the use for the treatment of anemia in patients undergoing dialysis.